APA (7th ed.) Citation

CF, F., C, S., CR, C., KS, P., DK, W., A, R., . . . J, W. (2022). Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: Clinical outcomes and translational biomarker analyses. Journal for immunotherapy of cancer, 10(1), . https://doi.org/10.1136/jitc-2021-003853

Chicago Style (17th ed.) Citation

CF, Friedman, et al. "Ipilimumab Alone or in Combination with Nivolumab in Patients with Advanced Melanoma Who Have Progressed or Relapsed on PD-1 Blockade: Clinical Outcomes and Translational Biomarker Analyses." Journal for Immunotherapy of Cancer 10, no. 1 (2022). https://doi.org/10.1136/jitc-2021-003853.

MLA (9th ed.) Citation

CF, Friedman, et al. "Ipilimumab Alone or in Combination with Nivolumab in Patients with Advanced Melanoma Who Have Progressed or Relapsed on PD-1 Blockade: Clinical Outcomes and Translational Biomarker Analyses." Journal for Immunotherapy of Cancer, vol. 10, no. 1, 2022, https://doi.org/10.1136/jitc-2021-003853.